|
|
||||||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
* Immunobiology Group, Medical Research Council Centre for Inflammation Research, University of Edinburgh, Queens Medical Research Institute, Edinburgh, United Kingdom
| Abstract |
|---|
|
|
|---|
| Introduction |
|---|
|
|
|---|
There are difficulties in the study of asthma in patients with established disease, and murine models have been extensively used to examine the role of the acquired immune response in induction of allergic airway inflammation (AAI)5 in sensitized animals (3, 5, 6, 7, 8, 9, 10, 11). Most of these studies examine events within the lungs 3–4 days after challenge, but there are fewer studies on the kinetics of resolution of disease markers after cessation of allergen exposure (12). The most widely used model system is OVA-induced allergy. However, although OVA is a gut allergen in humans (13), which may induce respiratory symptoms in a minority of patients when ingested (13), it is not a natural inducer of asthma. Using such models, the essential role of T cells in induction of AAI through Th2 development and the secretion of the cytokines IL-4, IL-5, IL-9, and IL-13 is well documented (14, 15). However, how T cells control the local airway immune response and their role in resolution of lung inflammation is still under characterized. It is widely accepted that allergic disease and asthma may be linked to a dysregulation in immune balance and in recent years, regulatory T cells (Tregs) have been demonstrated to play an essential role control of both innate and adaptive immune responses during Th2-mediated AAI (11, 16, 17, 18). Other studies have used murine models of OVA-induced AAI and TCR transgenic animals to determine the role of Ag-specific Tregs in induction and resolution of allergen-induced inflammation (11, 19, 20). Adoptive transfer of Ag-specific Tregs was reported to prevent induction of OVA-induced airway hyperreactivity, lung eosinophilia, and Th2 cytokine production in the lung (11). In a study using whole house dust mite extract as allergen, Lewkowich et al. (18) showed that depleting anti-CD25 Ab given to C3H mice before sensitization enhanced the allergic airway response but had no effect on the response in A/J mice and also increased the ability of lung DCs from C3H but not A/J mice to present the Ag.
However, there is still little information on the normal role of Tregs in resolution of airway inflammation or on whether transgenic Ag-specific Tregs act differently from naturally occurring or endogenously generated Tregs in sensitized wild-type animals. Naturally occurring Tregs constitutively express both CD25 and Foxp3 and constitute up to 10% of the peripheral T cell pool in naive animals (21). CD25+CD4+Foxp3+ T cells regulate immune responses through the secretion of immunosuppressive cytokines such as IL-10 and TGFβ (21, 22, 23). Previous work showed that induction of nasal tolerance to Der p1 inhibits lung inflammation and is associated with increased IL-10 secretion (10) although it was not investigated whether Tregs were involved.
This paper focuses for the first time on the role of CD25+CD4+Foxp3+ Tregs in control of AAI induced by the defined, natural airway allergen, house dust mite-derived native Der p1 protein, in sensitized animals with an intact nontransgenic immune system. We have used both depletion and adoptive transfer of Tregs to look at disease markers, Treg migration and function, and immune responses in both lungs and draining mediastinal lymph nodes (dMLN). Our data demonstrate a clear, novel role for naturally occurring CD25+CD4+Foxp3+ T cells. Upon airway challenge of Der p1-sensitized mice Tregs migrate into both lungs and dMLN and peak in number just before the start of resolution of disease markers. Depletion of CD25+CD4+Foxp3+ cells before airway challenge exacerbates AAI leading to elevated eosinophilia in both lung tissue and bronchoalveolar lavage, elevated titers of Ag-specific IgE, and expanded populations of Th2 cytokine-producing cells in the lymph node. Furthermore, adoptive transfer of CD25+CD4+Foxp3+ Treg from Ag naive syngeneic mice before airway challenge leads to their recruitment to dMLN, and both abrogates lung inflammation and the allergen-induced immune response within the dMLN. Surprisingly, blocking IL-10R function had no effect on the function of these Ag naive CD25+CD4+Foxp3+ Tregs in preventing lung inflammation but did restore the ability of dMLN cells to secrete Th2 cytokines suggesting that Treg control of AAI and effector T cell expansion in lymph nodes operate through different mechanisms. Overall, this study identifies a clear role for CD25+CD4+Foxp3+ Tregs in control and in resolution of AAI.
| Materials and Methods |
|---|
|
|
|---|
Female C57BL/6J mice (6–8 wk old) (Harlan-Olac) were housed in conventional specific and opportunistic pathogen-free facilities. All experiments were performed in accordance with the U.K. Home Office Scientific Procedures Act (1986) and local ethical approval.
Sensitization, airway challenge, and in vivo Ab treatment
As shown in Fig. 1, mice were sensitized by two i.p. injections of 10 µg of Der p1 absorbed on 2.25 mg of aluminum hydroxide (Imject ALUM; Pierce) in 100 µl. AAI was induced by two intratracheal (i.t.) instillations of 10 µg of Der p1 in 50 µl of PBS in anesthetized animals (0.1 mg/g Avertin; 2,2,2-tribromoethanol). Sensitized control mice were mock challenged with PBS. Der p1 was provided by Prof. Wayne Thomas (Institute of Child Health, Australia) or purchased from Indoor Biotechnology. Mice were treated i.p. with 250 µg of depleting anti-CD25 Ab (clone PC61), 7 days before airway challenge or with 500 µg of anti-IL-10R-blocking Ab (1B1.2) 1 day before challenge. Control mice received isotype control i.p. All Abs were purified from hybridoma supernatants using protein G-coupled Sepharose beads (Amersham Biosciences).
|
CD4+CD25+ cells were isolated from spleens of naive mice to 92% (±3%) purity using MACS bead mouse CD4+CD25+ Treg isolation kit (Miltenyi Biotec). CD4+CD25– cells were isolated from the negative fraction using MACS CD4+ positive selection kit to a purity of 98% (±2%). All isolated CD25+CD4+ cells were also Foxp3+ by flow cytometry. Preliminary experiments established that 5 x 105 Treg cells per recipient i.v. gave consistent results. To track transferred Tregs in vivo, cells were labeled with 5 µM CFSE before being transferred to Der p1-sensitized animals 1 day before i.t. challenge.
Bronchoalveolar lavage (BAL)
Mice were killed by i.p. injection of pentobarbitone. The trachea was exposed and cannulated with a 27-gauge needle encased in 0.96-mm silicon tubing (Portex). Lungs were lavaged three times with 500 µl of PBS followed by 800 µl of fresh PBS also instilled three times. Samples were centrifuged at 300 x g for 5 min at 4°C, and supernatant from the first wash stored at –20°C. Cell pellets were resuspended in 500 µl of PBS and cytospins prepared by cytocentrifugation (Shandon) at 300 rpm for 3 min. Slides were air-dried, methanol fixed, and stained with Diff Quik (CellPath Store). Differential cell counts were performed blinded to experimental details (by S.E.M.H.).
Histological and immunohistochemical analysis of lung tissue
After BAL, lungs were perfused with PBS and for histological examination were inflated with and fixed in 4% neutral buffered formalin before paraffin embedding. Sections (3 µm) were stained with H&E for assessment of inflammation and periodic acid-Schiff for goblet cell hyperplasia. Inflammation was scored for each mouse at x200 magnification by averaging the score of 10 consecutive fields where the lungs were correctly inflated and the field contained a complete transection of at least one bronchiole (less than half a field width/300 µm in diameter), blood vessels, and alveolar airway. Inflammation was scored on an increasing severity score of 1–4 in the perivascular compartment (1, no cells; 2, <20 cells; 3, <100; and 4, >100 cells): the bronchiolar epithelium (1, no cells; 2, <5; 3, <10; and 4, >10 cells): the peribronchiolar alveolar tissue (1, no cells; 2, <20; 3, <100; and 4, >100 cells): and the alveolar walls (1, normal; 2, focal cellular expansion of the alveolar walls by 2–3 cells; 3, by 4–5 cells; 4, >5 cells). Eosinophilia was determined as the percentage of infiltrating cells in lung tissue (not airspaces) and was additionally confirmed in some experiments with a monoclonal eosinophil-specific Ab supplied by Dr. J. Lee (Mayo Clinic, Rochester, MN) (24). Goblet cell hyperplasia was scored on 10 airways at a magnification of x400 and is expressed as the average percentage of goblet cells/airway. Histological scores were performed blinded to experimental details (S.E.M.H.).
Lymph node and lung lymphocyte restimulation
Single cell suspensions of dMLN and PBS perfused whole lungs were made by passing tissues through 40-µm sterile sieves. Lung cells were then spun over Lympholyte-M (VH-Bio) to isolate mononuclear leukocytes. Cells were washed, resuspended in complete medium (RPMI 1640 supplemented with 10% FCS, 100 U/ml penicillin, 100 µg/ml streptomycin, 2 mM L-glutamine, and 50 µM 2-ME; Sigma-Aldrich) plated in 96-well microplates at 5 x 105 cells/well and cultured with medium alone or 50 µg/ml Der p1. Because numbers of cells were always limiting, preliminary experiments indicated that removing 48 h supernatants for cytokines, labeling the same wells with 0.5 µCi [3H]thymidine and counting incorporation at 72 h in a beta plate scintillation counter (Wallac U.K.) gave consistent results. Supernatants were stored at –80°C before analysis using a mouse inflammatory cytokine bead array (BD Biosciences) and commercially available ELISA kits (IL-5, BD Biosciences; IL-13, R&D Systems). In some experiments, proliferation was measured by flow cytometry using a live lymphocyte gate following incubation of cells with 5 µM CFSE for 15 min at 37°C, followed by washing, before culturing for 72 h as above.
Analysis of Tregs
Single cell suspensions from dMLN or lungs were resuspended at 5 x 106 cells/ml and stained with extracellular CD4 and CD25 (BD Pharmingen) and intracellular Foxp3 as recommended by the manufacturer (eBioscience). CD25 depletion was confirmed by analysis with
CD25 Abs (clones 7D4 and 3C7) and flow cytometry on a BD FACSCalibur using CELLQuest software.
Der p1-specific IgG1, IgG2a, and IgE
Microtiter wells were coated with 0.25 µg of Der p1 in 50 µl of 0.05 M carbonate bicarbonate buffer (pH 9.6). Nonspecific binding was blocked with 3% BSA in PBS. For IgG1 and IgG2ab analysis, sera were double diluted from a 1/20 dilution in PBS-T (PBS containing 0.05% Tween 20). Bound Ab was detected using biotinylated rat anti-mouse IgG1 (clone LO-MG1-2; Serotec) or biotinylated mouse anti-mouse IgG2ab (clone 5.7; BD Pharmingen). For IgE measurement, sera were depleted of IgG using protein G-coupled beads (25) and double diluted from a 1/10 dilution in PBS-T. Bound Ab was detected using biotinylated rat anti-mouse IgE (clone R35-118; BD Pharmingen). Binding was visualized using streptavidin-HRP (R&D Systems) and tetramethylbenzidine (R&D Systems).
Statistical analysis
Mann-Whitney tests were used to determine statistical differences between groups, where a value of p < 0.05 was considered to be significant.
| Results |
|---|
|
|
|---|
To establish a time course of AAI resolution, a highly reproducible, minimal sensitization and challenge model was established in C57BL/6J mice. Mice were sensitized i.p. twice with Der p1 in alum adjuvant and challenged i.t. twice with Der p1 in PBS. Control sensitized mice were mock challenged with PBS (Fig. 1). Animals that received no sensitizing injection, only one sensitizing injection, or only one i.t. challenge did not develop AAI (data not shown). The time between last sensitization and first challenge could vary between 14 and 28 days without effect on AAI (data not shown). After the second challenge, mononuclear cells and eosinophils infiltrated into perivascular, peribronchiolar and bronchiolar lung tissue and into alveolar walls (Fig. 2). By day 2 post challenge, mice given Der p1 had moderate to severe lung inflammation in all compartments (Fig. 3, A–D), which resolved by day 21. The maximal eosinophil influx in lung tissue and BAL coincided with the peak in inflammation and gradually declined over time reaching control levels by day 21 (Figs. 2B; and 3, E and F). Goblet cell hyperplasia (Figs. 2D and 3G) peaked on day 4 post challenge but was not completely resolved by day 21. PBS-challenged mice were included at each time point but never developed AAI (Fig. 2, E and F) and are represented as a pooled PBS group (Fig. 3).
|
|
Local (dMLN) and systemic (serum antibody) adaptive immune responses to airway challenge were determined. Although mock-challenged (PBS) mice had very small lymph nodes compared with Der p1-challenged animals, dMLN cells from both groups proliferated when incubated with Der p1 because they had all been sensitized. This indicated that Ag-reactive memory cells had spread through the lymphoid system after sensitization (Fig. 4A). The proliferative response of dMLN cells in medium alone were always <1000 cpm (not shown). Cells from Der p1-challenged mice produced high levels of IL-5, IL-10, and IL-13 in response to Ag recall. IL-4 was measured in preliminary experiments but levels were low and variable at the 48 h time point, and it was decided to concentrate on IL-5 and IL-13 as indicators of allergic Th2 activation. dMLN cells produced <100 pg/ml of any cytokine when grown in medium alone (data not shown). Cytokine release and proliferation peaked in cells cultured from day 4 post challenge and declined thereafter (Fig. 4, A–D). This indicated that as the lung response resolved, the numbers of effector cells in dMLN decreased. Despite showing equivalent proliferative responses to Der p1, dMLN cells from mock-challenged mice secreted much less IL-5 and IL-13 and essentially no IL-10 when stimulated with Der p1 (Fig. 4, B–D). This indicated that although Der p1-reactive memory was similar in lymphoid tissue of both groups, the challenged mice had expanded allergic effector cell populations. IFN-
was always undetectable in cells from mock or Der p1-challenged mice.
|
and IL-4 were undetectable. BAL collected at all other time points or from mock-challenged mice at any time point contained no detectable cytokines (not shown). Sera from sensitized mice 2 days after challenge with PBS or Der p1 had similar levels of specific IgG1 (Fig. 4I). However, by day 21, Der p1-challenged mice had enhanced serum IgG1 (Fig. 4J). In contrast, Der p1-specific IgE titers were enhanced at day 2 post challenge with Derp1 (Fig. 4K), but by day 21 this declined almost to the level of mock-challenged mice (Fig. 4L). Der p1-specific IgG2ab was undetectable at all time points (not shown).
CD4+CD25+Foxp3+ Tregs increase in the lung and dMLN upon Ag challenge
Endogenous CD4+CD25+Foxp3+ Tregs have been implicated in suppression of responses to foreign Ag, thus we aimed to investigate whether Tregs were involved in resolution of Der p1-induced AAI. Fig. 5 shows that low numbers of Treg cells were found in both dMLN and lungs of mock-challenged mice. After allergen challenge the numbers of CD4+Foxp3+CD25+Tregs significantly increased at day 4 and declined over time. In both dMLN and lung there was a consistent, detectable population of CD4+Foxp3+CD25– cells, which was not changed either by allergen challenge or over time.
|
Having shown that Tregs accumulated in lungs and dMLN after allergen challenge we wished to know whether or not they were involved in resolution of AAI. Mice were given a single dose of 250 µg of anti-CD25 Ab (PC61) i.p. to deplete endogenous CD25+ Tregs or received additional (5 x 105) purified Tregs i.v. from allergen naive syngeneic donors. Preliminary experiments established that CD4+Foxp3+CD25+ cells were undetectable in spleens of PC61-treated animals 7 days after Ab administration and were still 75% depleted after 17 days, whereas treatment had no effect on the CD4+Foxp3+CD25– population (Fig. 6). To test Treg function, depleting Ab was given 14 days after second sensitization (Fig. 1) when effector T cells were not detectable in dMLN, and mice were then rested for 7 days before first i.t. challenge to allow clearance of the anti-CD25 Ab.
|
To assess Treg function in AAI, tissues were analyzed at day 6 post challenge when inflammation was well established, but starting to resolve (Figs. 2–4). In depletion experiments, isotype Ab i.p. and PBS i.p. were both used as controls for PC61 administration. Because these control treatments gave equivalent results in three separate experiments (p > 0.05), they are expressed as a total control group. Anti-CD25 Ab had no effect on overall lung inflammation (Fig. 7, A–D) indicating that mice were still capable of mounting a response to allergen challenge, i.e., depletion had not removed memory cells. However, there was increased eosinophilia in the pulmonary tissue (Fig. 7E) and BAL (Fig. 7F). In contrast, transfer of CD4+CD25+Foxp3+ T cells from naive mice before airway challenge reduced disease as lung inflammation and eosinophilia was almost completely absent (Fig. 7). Transfer of CD4+CD25– cells had no effect.
|
Transfer and depletion of CD25+Foxp3+ T cells before airway challenge had profound effects on lung pathology. Whether transfer or depletion also reduced or exacerbated the adaptive allergic responses was investigated by determining the dMLN T cell response and serum Ab levels. Depletion of CD25+Foxp3+ T cells enhanced proliferation of dMLN cells to recall Ag (Fig. 8A). This coincided with elevated levels of the Th2 cytokines, IL-5 (Fig. 8B), and IL-13 (Fig. 8C) but there was no effect on IL-10 secretion (Fig. 8D). In contrast, adoptive transfer of CD25+Foxp3+ T cells abrogated proliferation and decreased secretion of IL-5 and IL-13 (Fig. 8, A–C), but enhanced levels of IL-10 compared with CD25– cell recipients or control mice (Fig. 8D). Depletion of CD25+ T cells increased IgG1 and IgE whereas transfer inhibited Ab titers compared with control mice (Fig. 8, E–H).
|
CD25+Foxp3+ transfer increased production of IL-10 by dMLN cells from Der p1-challenged mice. To resolve whether IL-10 was important in prevention or early resolution of pulmonary inflammation, anti-IL-10R-blocking Ab was administered at the time of cell transfer. Blockade of IL-10R at the time of cell transfer had no effect on the inhibition of lung inflammation (Fig. 9, A–D) or on eosinophilia (Fig. 9, E and F).
|
Fig. 10, A–D, shows that, as above, adoptive transfer of CD25+Foxp3+CD4+T cells decreased dMLN cell proliferation and this coincided with decreased IL-5 and IL-13 and increased IL-10 secretion. Administration of anti-IL-10R Ab at the time of transfer prevented the decreased proliferation and cytokine secretion.
|
As above, transfer of CD25+Foxp3+ cells before airway challenge prevented secretion of Der p1-specific IgG1 and IgE Abs. Blockade of IL-10R binding at the time of transfer did not reverse this response in cell recipients (Fig. 10, E and G). Levels of IgG2ab were low in all groups of mice (Fig. 10F).
| Discussion |
|---|
|
|
|---|
Previous studies reported on induction and modulation of AAI in murine models (15, 26) and TCR transgenic OVA-specific Tregs have been shown to down-regulate AAI in an IL-10-dependent fashion (11). However, this study did not determine whether endogenous Tregs were involved in induction and resolution of AAI, nor whether Tregs must be allergen-specific to control AAI. Using whole house dust mite extract as allergen, Lewkowich et al. (18) showed that depletion of natural CD25+CD4+ T cells before sensitization increased disease in C3H but not A/J mice and that this was due to alterations in lung dendritic cells. This study demonstrated that natural Tregs are important in determining whether allergy results from allergen encounter but did not determine whether disease can be modulated by endogenous Tregs in already sensitized animals.
To determine whether Tregs were involved in AAI resolution and associated immune responses, we first established the time course of lung inflammation and systemic immunity in Der p1-sensitized and -challenged mice. Lung inflammation and eosinophilia peaked between 2 and 6 days after challenge and had largely returned to baseline levels by 21 days (Figs. 2 and 3). Serum Der p1-specific IgE levels were transiently boosted by i.t. challenge but decreased by 21 days whereas serum IgG1 levels were boosted by challenge and continued to increase 21 days later (Fig. 4). Recall responses in dMLN cells showed that effector cells capable of secreting IL-5, IL-13, and IL-10 were present in draining lymph nodes from 2 days after challenge and decreased by 21 days (Fig. 4).
We further demonstrated that CD25+CD4+Foxp3+ cells are recruited into both lungs and draining lymph nodes of sensitized mice, peaking at 4 days after challenge when resolution starts (Fig. 5). To study whether these cells were functionally involved in resolution and/or disease induction we took a "two sided" approach of in vivo endogenous Treg depletion and adoptive transfer. When using depleting anti-CD25 Ab in sensitized animals it was a concern that we may simply remove effector T cells so sufficient time had to be left after sensitization to allow activated allergen-specific CD25+ effector cells to revert to "memory" i.e., CD25– status. That depletion before lung challenge did not appear to alter the overall lung inflammation (Fig. 7) and enhanced serum Ab responses (Fig. 8) indicated that treatment did not prevent generation of effector cells from pre-existing memory cells. However, Treg depletion resulted in elevated eosinophilia (Fig. 7) and enhanced Der p1-specific serum IgG1 and IgE responses (Fig. 8). This indicates that Tregs normally "dampen down" AAI but cannot prevent eosinophilia and allergic Ab production induced by lung challenge. The results are consistent with previous reports that have suggested that Tregs are important in control of Th2 immune responses and lung eosinophilia (11, 20).
Other studies reported that Ag-specific Treg from DO11.10 transgenic mice can suppress lung eosinophilia. To establish whether or not endogenous Treg from allergen naive, wild-type mice would also be functional in AAI modulation, we transferred 5 x 105 CD4+CD25+Foxp3+ T cells from naive mice into sensitized animals 1 day before allergen challenge. These cells were recruited to and retained in dMLN after Ag challenge (Fig. 6). Treg transfer had the opposite effect of depletion and greatly reduced lung eosinophilia (Fig. 7) and goblet cell differentiation (data not shown) as well as inhibiting production of Der p1-specific serum IgE and IgG1 (Fig. 8).
Treg depletion enhanced levels of the Th2 cytokines, IL-5 and IL-13 secreted by dMLN cells while transfer of additional Tregs from allergen naive mice had opposite effects (Fig. 8). In contrast, IL-10 secreted by dMLN cells was unaffected by depletion but enhanced by transfer. The question arose from this whether IL-10 was necessary for Treg function in control of Der p1-induced AAI. To answer this, we treated mice with IL-10R blocking Ab at the time of Treg transfer. Unlike results reported for TCR transgenic OVA-specific Tregs (11), control of AAI in our model is independent of IL-10R signaling as administration of anti-IL-10R Ab at the time of Treg transfer had no effect (Fig. 10). In contrast, in the dMLN response, blockade of IL-10 signaling at the time of transfer prevented the inhibition of IL-5 and IL-13 seen when Tregs alone were given (Fig. 10). This indicates that IL-10 is necessary for Treg control of dMLN IL-5 and IL-13 secretion. Levels of IL-10 secretion by dMLN cells were unaffected by receptor blockade (Fig. 10).
Overall these results show that endogenous Tregs control resolution of airway inflammation and eosinophilia in the lung in an IL-10 independent manner while draining lymph node allergic Th2 cytokine responses are controlled by the same cell population in an IL-10-dependent manner. We believe that our results showing that natural/endogenous Tregs are important for resolution of AAI and that their function can be boosted by transferring cells from Ag naive donors add important information on the biology of AAI and credence to the idea that endogenous Tregs may be a therapeutic target.
| Disclosures |
|---|
|
|
|---|
| Footnotes |
|---|
1 This work was supported by the European Community, the Medical Research Council, and the Norman Salvesen Emphysema Research Trust. ![]()
2 Current address: Institute of Immunology and Infection Research, Kings Buildings, University of Edinburgh, West Mains Road, Edinburgh, Scotland. ![]()
3 Current address: Centre for Biophotonics, Strathclyde Institute for Biomedical Sciences, University of Strathclyde, 27 Taylor Street, Glasgow, U.K. ![]()
4 Address correspondence and reprint requests to Dr. Sarah Howie, Immunobiology Group, Medical Research Council Centre for Inflammation Research, University of Edinburgh, Queens Medical Research Institute, 47 Little France Crescent, Edinburgh, EH16 4TJ Scotland. E-mail address: s.e.m.howie{at}ed.ac.uk ![]()
5 Abbreviations used in this paper: AAI, allergic airway inflammation; dMLN, draining mediastinal lymph node; i.t., intratracheal; Treg, regulatory T cell; BAL, bronchoalveolar lavage. ![]()
Received for publication December 13, 2006. Accepted for publication August 30, 2007.
| References |
|---|
|
|
|---|
regulate allergic airway inflammation and mucus production. J. Exp. Med. 190: 1309-1317. This article has been cited by other articles:
![]() |
K. Karimi, M. D. Inman, J. Bienenstock, and P. Forsythe Lactobacillus reuteri-induced Regulatory T cells Protect against an Allergic Airway Response in Mice Am. J. Respir. Crit. Care Med., February 1, 2009; 179(3): 186 - 193. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. A. Doherty, P. Soroosh, D. H. Broide, and M. Croft CD4+ cells are required for chronic eosinophilic lung inflammation but not airway remodeling Am J Physiol Lung Cell Mol Physiol, February 1, 2009; 296(2): L229 - L235. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Vultaggio, F. Nencini, P. M. Fitch, L. Fili, L. Maggi, P. Fanti, A. deVries, E. Beccastrini, F. Palandri, C. Manuelli, et al. Modified Adenine (9-Benzyl-2-Butoxy-8-Hydroxyadenine) Redirects Th2-Mediated Murine Lung Inflammation by Triggering TLR7 J. Immunol., January 15, 2009; 182(2): 880 - 889. [Abstract] [Full Text] [PDF] |
||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |